We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights Amazon, Sanofi, Target, Humana and PNC Financial Services
Read MoreHide Full Article
For Immediate Release
Chicago, IL – November 14, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Amazon (AMZN - Free Report) , Sanofi (SNY - Free Report) , Target Corp. (TGT - Free Report) , Humana Inc. (HUM - Free Report) and The PNC Financial Services Group, Inc. (PNC - Free Report) .
Here are highlights from Friday’s Analyst Blog:
Top Stock Reports for Amazon, Sanofi and Target
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Amazon, Sanofi and Target Corp. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Shares of Amazon.com have declined -45.2% over the past year against the Zacks Internet - Commerce industry’s decline of -48.6% and the -17.1% decline in the S&P 500 index.
Weighing on Amazon's near-term outlook is the view that the company's strong growth during Covid resulted from pulled forward revenues from future periods that need to be accounted for over the next few quarters. The company is also believed to have over-hired during the pandemic, as a result of which its cost base has signficantly increased.
These near-term headwinds aside, it is gaining on solid Prime momentum owing to ultrafast delivery services and strong content portfolio. Strengthening relationship with third-party sellers is another positive.
Also, growing momentum across Amazon Music is contributing well. Additionally, strong adoption rate of AWS is aiding the company’s cloud dominance. Expanding AWS services portfolio is continuously helping Amazon in gaining further momentum among the customers.
Further, robust Alexa skills and expanding smart home products portfolio are positives. Additionally, the company’s strong global presence and solid momentum among the small and medium businesses remain tailwinds. Considering the abovementioned facts, the Zacks analyst expect 2022 revenue to be up 11% from 2021.
Sanofi’s shares have underperformed the Zacks Large Cap Pharmaceuticals industry over the past year (-12.7% vs. +10.7%). The company is facing headwinds include weak performance of diabetes drugs and generic competition for many drugs. However, Sanofi’s Specialty Care unit is on a strong footing, particularly with the regular label expansion of Dupixent.
Dupixent has become the key top-line driver for Sanofi. With outside U.S. revenues accelerating and multiple approvals for new indications expected in the near future, its sales are expected to be higher. Sanofi possesses a leading vaccine portfolio, which has become the primary top-line driver. Its R&D pipeline is strong.
Several data read-outs are expected in 2022. Sanofi’s Consumer unit is delivering above market sales growth. Sanofi has also launched several new drugs in the past couple of years and is expanding its pipeline through M&A deals.
Target’s shares have declined -24.7% this year vs. Walmart's -1.5% drop and the S&P 500 index's -18.2% drop. The market has been unwilling to give Target credit for the inventory growth issue that came through in its April-quarter report in May. This is a relatively favorable set up for the stock should next week's quarterly report turns out to be better than what the market fears.
Target has been deploying resources to enhance omni-channel capabilities, come up with new brands, refurbish stores and expand same-day delivery options to provide customers seamless shopping experience.
Target has been making multiple changes to its business model to adapt and stay relevant in the dynamic retail landscape. These have been contributing to the top line. We believe that Target’s attempt to right-size inventory is the step in the right direction, as the demand skewed toward consumer staples and away from discretionary categories.
However, this hurt margins as was visible in the second quarter of fiscal 2022 but better position the company to gain market share. The Zacks analyst expect top line to increase 3% and 4.2% in the third- and fourth-quarter, respectively. For the back half of the year, we expect operating margin to improve sequentially.
Other noteworthy reports we are featuring today include Humana Inc. and The PNC Financial Services Group, Inc.
Why Haven’t You Looked at Zacks' Top Stocks?
Our 5 best-performing strategies have blown away the S&P's impressive +28.8% gain in 2021. Amazingly, they soared +40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today you can access their live picks without cost or obligation.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights Amazon, Sanofi, Target, Humana and PNC Financial Services
For Immediate Release
Chicago, IL – November 14, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Amazon (AMZN - Free Report) , Sanofi (SNY - Free Report) , Target Corp. (TGT - Free Report) , Humana Inc. (HUM - Free Report) and The PNC Financial Services Group, Inc. (PNC - Free Report) .
Here are highlights from Friday’s Analyst Blog:
Top Stock Reports for Amazon, Sanofi and Target
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Amazon, Sanofi and Target Corp. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Shares of Amazon.com have declined -45.2% over the past year against the Zacks Internet - Commerce industry’s decline of -48.6% and the -17.1% decline in the S&P 500 index.
Weighing on Amazon's near-term outlook is the view that the company's strong growth during Covid resulted from pulled forward revenues from future periods that need to be accounted for over the next few quarters. The company is also believed to have over-hired during the pandemic, as a result of which its cost base has signficantly increased.
These near-term headwinds aside, it is gaining on solid Prime momentum owing to ultrafast delivery services and strong content portfolio. Strengthening relationship with third-party sellers is another positive.
Also, growing momentum across Amazon Music is contributing well. Additionally, strong adoption rate of AWS is aiding the company’s cloud dominance. Expanding AWS services portfolio is continuously helping Amazon in gaining further momentum among the customers.
Further, robust Alexa skills and expanding smart home products portfolio are positives. Additionally, the company’s strong global presence and solid momentum among the small and medium businesses remain tailwinds. Considering the abovementioned facts, the Zacks analyst expect 2022 revenue to be up 11% from 2021.
(You can read the full research report on Amazon.com here >>>)
Sanofi’s shares have underperformed the Zacks Large Cap Pharmaceuticals industry over the past year (-12.7% vs. +10.7%). The company is facing headwinds include weak performance of diabetes drugs and generic competition for many drugs. However, Sanofi’s Specialty Care unit is on a strong footing, particularly with the regular label expansion of Dupixent.
Dupixent has become the key top-line driver for Sanofi. With outside U.S. revenues accelerating and multiple approvals for new indications expected in the near future, its sales are expected to be higher. Sanofi possesses a leading vaccine portfolio, which has become the primary top-line driver. Its R&D pipeline is strong.
Several data read-outs are expected in 2022. Sanofi’s Consumer unit is delivering above market sales growth. Sanofi has also launched several new drugs in the past couple of years and is expanding its pipeline through M&A deals.
(You can read the full research report on Sanofi here >>>)
Target’s shares have declined -24.7% this year vs. Walmart's -1.5% drop and the S&P 500 index's -18.2% drop. The market has been unwilling to give Target credit for the inventory growth issue that came through in its April-quarter report in May. This is a relatively favorable set up for the stock should next week's quarterly report turns out to be better than what the market fears.
Target has been deploying resources to enhance omni-channel capabilities, come up with new brands, refurbish stores and expand same-day delivery options to provide customers seamless shopping experience.
Target has been making multiple changes to its business model to adapt and stay relevant in the dynamic retail landscape. These have been contributing to the top line. We believe that Target’s attempt to right-size inventory is the step in the right direction, as the demand skewed toward consumer staples and away from discretionary categories.
However, this hurt margins as was visible in the second quarter of fiscal 2022 but better position the company to gain market share. The Zacks analyst expect top line to increase 3% and 4.2% in the third- and fourth-quarter, respectively. For the back half of the year, we expect operating margin to improve sequentially.
(You can read the full research report on Target here >>>)
Other noteworthy reports we are featuring today include Humana Inc. and The PNC Financial Services Group, Inc.
Why Haven’t You Looked at Zacks' Top Stocks?
Our 5 best-performing strategies have blown away the S&P's impressive +28.8% gain in 2021. Amazingly, they soared +40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.